Core Viewpoint - The announcement from Yong'an Pharmaceutical indicates that the actual controller and chairman, Chen Yong, has had his detention measures lifted, allowing him to resume normal duties, which is expected to stabilize the company's management [2][4]. Group 1: Company Background - Yong'an Pharmaceutical is a leading enterprise in the taurine industry, primarily engaged in the research, production, and sales of taurine products, health foods, and special dietary foods [6]. - The company holds approximately 50% of the global market share in taurine production, with an annual production capacity of 58,000 tons, making it a key supplier for major global brands like Red Bull, Nestlé, and Coca-Cola [6]. Group 2: Financial Performance - The company's financial performance has shown a downward trend, with revenues decreasing from 1.462 billion yuan in 2022 to 839 million yuan in 2024, and net profits declining from 133 million yuan to a loss of 28.41 million yuan during the same period [7]. - In the first half of the current year, Yong'an Pharmaceutical reported revenues of 367 million yuan, a year-on-year decline of 13.7%, and a net profit of 8.55 million yuan, down 83% compared to the previous year [7]. Group 3: New Business Prospects - The company is focusing on the development of creatine products, which are still in the early stages and unlikely to significantly boost performance in the short term [9]. - Yong'an's subsidiary, Ling'an Technology, is undergoing a business transformation to develop monohydrate creatine, leveraging existing production and sales channels to enhance growth potential [9]. - Investors are particularly interested in whether Chen Yong's return will help the company overcome its performance challenges and if the new business initiatives can serve as a growth engine [9].